- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Streamlining Prior Authorization for Topical AD Therapies: Expert Strategies
Atopic dermatitis experts examine factors that impact coverage decisions for atopic dermatitis (AD) treatments, address challenges providers encounter (such as step-therapy and prior authorization) and offer strategies to streamline the prior authorization process for topical AD therapies.
EP: 1.Tackling Key Concerns in Atopic Dermatitis + Biologic Use
EP: 2.Atopic Dermatitis: Topical Therapies and Unmet Needs in the Treatment Landscape
EP: 3.Going Beyond Topical Steroids and Calcineurin Inhibitors for AD Treatment
EP: 4.Experts Discuss Long-Term Effects and Monitoring in AD Therapy
EP: 5.Balancing Safety and Efficacy: Optimizing Topical Treatment Options for AD
EP: 6.The Patient Journey: Effectively Managing AD Itch Early On
EP: 7.Streamlining Prior Authorization for Topical AD Therapies: Expert Strategies
EP: 8.Experts Share Final Insights to Optimize Atopic Dermatitis Patient Care
- In addition to cost, what factors influence coverage decisions for AD treatments?
- How do step-therapy protocols and prior authorization approval process influence the prescribing patterns of topical therapies (and progressing to systemic therapies) for AD among healthcare providers?
- What strategies can healthcare providers implement to streamline the PA approval process for topical AD therapies and reduce administrative burdens while still ensuring cost-effective care?
- Please discuss the burden providers face in terms of workload perspective, staffing constraints, etc, and what this means for patients
High HSP60 Expression Signals Poor Prognosis, Aggressive Tumors in Ovarian Cancer
January 16th 2025High heat shock protein 60 (HSP60) expression in patients with ovarian cancer is associated with larger tumors, advanced stages, and worse survival outcomes, highlighting its potential as a prognostic biomarker.
Read More
Real-World Evidence Confirms the Benefits of JAK Inhibitors in Patients With Rheumatoid Arthritis
January 16th 2025This systematic review of real-world observational studies demonstrated the effectiveness of Janus kinase (JAK) inhibitors in improving treatment adherence, persistence, clinical outcomes, and patient-reported outcomes among US patients with rheumatoid arthritis.
Read More
